• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Schering extends deal with NeXstar

Article

German contrast agent firm Schering has extended its ongoing R&Dcollaboration with pharmaceutical developer NeXstar of Boulder,CO, for the development of in vivo imaging agents using NeXstar'sSelex combinatorial chemistry process. Schering increased

German contrast agent firm Schering has extended its ongoing R&Dcollaboration with pharmaceutical developer NeXstar of Boulder,CO, for the development of in vivo imaging agents using NeXstar'sSelex combinatorial chemistry process. Schering increased itsresearch payments to NeXstar to $2.4 million a year from $1 milliona year as part of the deal.

Under the collaboration, NeXstar is using the Selex processto develop aptamers, which are short stretches of modified DNAor RNA that can bind to diagnostic targets in the body. Thesetargets can be identified by imaging modalities, and Scheringhas specified several cardiac and oncology applications it isinterested in pursuing.

Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Can 18F-Floutufolastat Bolster Detection of PCa Recurrence in Patients with Low PSA Levels After Radical Prostatectomy?
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.